Implemented data mining and signal management systems on spontaneous reporting systems' databases and their availability to the scientific community - a systematic review

Current Drug Safety

Volumn 7, Issue 2, 2012, Pages 170-175

  de Almeida Vieira Lima, Luís Miguel ^a   Nunes, Nuno Gonçalo Sales Craveiro ^a,b,c   da Silva Dias, Pedro Gonçalo Pires ^d,e,f,g   Marques, Francisco Jorge Batel ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^e POLYTECHNIC INSTITUTE OF LEIRIA   (Portugal)

^f Center of Investigation in Human Motricity   (Portugal)

^g RESEARCH CENTER IN SPORTS SCIENCES   (Portugal)

Author keywords

Data mining; Information system; Pharmacovigilance; Post marketing safety surveillance; Scientific community; Signal detection software; Spontaneous reporting system

Indexed keywords

ARTICLE; COMPUTER PROGRAM; DATA ANALYSIS; DATA BASE; DATA EXTRACTION; DATA MINING; DATA MINING AND SIGNAL MANAGEMENT SYSTEM; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMATION SYSTEM; MEDLINE; PRIORITY JOURNAL; SIGNAL DETECTION; SPONTANEOUS REPORTING SYSTEM; SYSTEMATIC REVIEW; WORLD HEALTH ORGANIZATION;

EID: 84870325115     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488612802715645     Document Type: Article

References (28)

1. Lu Z, Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives. Drug Healthc Patient Saf 2009: 1: 35-45.
2. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54: 315-21.
3. van Puijenbroek AB, Leufkens HGM, Lindquist M, Orre M, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11(1): 3-10.
4. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-thanexpected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002; 25(6): 381-92.
5. Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol; 2003 57(2): 127-34.
6. van Puijenbroek E, Diemont W, van Grootheest K. Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Saf 2003; 26 (5): 293-01.
7. Bate A. Bayesian confidence propagation neural network. Drug Saf 2007; 30(7): 623-25.
8. Lindquist M. VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Information J 2008; 42: 409-19.
9. Li C, Xia J, Deng J, et al. A web-based quantitative signal detection system on adverse drug reaction in China. Eur J Clin Pharmacol 2009; 65: 729-41.
10. Almenoff J. Innovations for the future of pharmacovigilance. Drug Saf 2007; 30(7): 631-3.
11. Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today 2009; 14(7/8) 343-57.
12. Bate A, Lindquist M, Edwards IR, Orre R. A data mining approach for signal detection and analysis. Drug Saf 2002; 25(6): 393-7.
13. Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther 2007; 82(2): 157-66.
14. Evans SJ, Waller PC, Davis S. Use proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10: 483-6.
15. Diane K, Wysowski LS. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002. Arch Intern Med 2005; 165: 1363-9.
16. Almenoff J, Tonning JM, Gould AL. Perspectives on the use of data mining in pharmacovigilance. Drug Saf 2005; 28(11): 981-1007.
17. Orre R. On Data mining and classification using a bayesian confidence propagation neural network, in Department of Numerical Analysis and Computer Science. Royal Institute of Technology: Stockholm, Sweden 2003.
18. FDA. Adverse Event Reporting System (AERS). 2009 [accessed 12/9/2011]; Available from: http://www.fda.gov/Drugs/Guidanc eComplianceRegulatoryInformation/Surveillance/AdverseDrugEffe cts/default.htm.
19. FDA. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. 2011 [accessed 12/9/2011]; Available from: http://www.fda.gov/Safety/MedWatch/default.htm.
20. Sten Olsson GB. UR 54. Uppsala Reports 2011; ISSN 1651-9779.
21. UMC. The WHO Global ICSR database. 2011 [accessed 12/9/2011]; Available from: http://www.who-umc.org/DynPage.aspx?id=101 247&mn1=7347&mn2=7252&mn3=7258.
22. EMA. Guideline on the use of statistical signal detection methods in the Eudravigilance data analysis system. 2006 [accessed 12/9/2011]; Available from: http://www.ema.europa.eu/docs/en _GB/document_library/Regulatory_and_procedural_guideline/200 9/11/WC500011434.pdf.
23. EMA. EudraVigilance 2011 [accessed 12/9/2011]; Available from: http://eudravigilance.ema.europa.eu
24. MHRA. Guidance Notes and Application Form for Access to Yellow Card and Adverse Drug Reactions On line Information Tracking (ADROIT) Data. 2004 [accessed 12/9/2011]; Available from: http://www.mhra.gov.uk/CON2023455.
25. MHRA. Yellow Card Scheme. 2011 12/9/2011]; Available from: http://yellowcard.mhra.gov.uk.
26. Lareb. Netherlands Pharmacovigilance Centre Lareb. 2011 [accessed 12/9/2011]; Available from: http://www.lareb.nl.
27. Phase-Forward. Post-marketing surveillance. 2010 [accessed 12/9/2011]; Available from: http://www.phaseforward.com/produ cts/safety/stratpharma
28. World Health Organization. UMC, Viewpoint Part 2, watching for safer medicines. The Uppsala Monitoring Centre 2005.